Comparative clinical pharmacology of amikacin and kanamycin in dairy calves.

The in vitro susceptibility of Escherichia coli, Salmonella sp, Pasteurella multocida, and Pseudomonas aeruginosa strains isolated from young calves and their environment to kanamycin and its semisynthetic derivative--amikacin, was compared by the tube dilution method. The minimal inhibitory concentration of amikacin was two- to fourfold lower than the minimal inhibitory concentration of kanamycin for the Salmonella group B, Ps aeruginosa and P multocida strains examined, whereas the E coli and Salmonella group D strains were eqaully susceptible to the 2 antibiotics. The concentrations of amikacin and kanamycin in the serum of calves after single intramuscular injections at 10, 25, and 50 mg/kg were determined, and differences between the 2 antibiotics were not observed. Intramuscular dosage schedules were calculated, based on the sensitivity of the different bacterial strains and the duration of effective serum drug concentrations.     

Clonidine in horses: identification, detection, and clinical pharmacology

Clonidine is classified as a class 3 performance-enhancing agent by the Association of Racing Commissioners International and thus has the potential to influence the outcome of a race. In this study, the authors developed and validated a sensitive gas chromatograph and mass spectrometer method to determine the pharmacokinetic parameters of clonidine in equine plasma samples after IV administration of a single dose (0.025 mg/kg) of clonidine in horses. At this dose, clonidine produced rapid and profound sedation, which cold be quickly reversed with yohimbine. Clonidine was able to produce an analgesic effect but failed to provide maximal analgesia in all horses; the limited analgesic effect persisted for about 60 minutes.     

The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors.

Over the past decade, there have been several nonsteroidal anti-inflammatory drugs (NSAIDS) introduced in veterinary medicine with an increased gastrointestinal safety profile consistent with a cyclooxygenase (COX)-1-sparing effect. More recently, an NSAID with additional 5-lipoxygenase (5-LOX) activity has also been approved for use. Although it is tempting to equate in vitro COX-2/COX-1 and 5-LOX inhibition to overall in vivo safety, the data do not support this approach. The true overall safety for any individual compound is based on its evaluation in laboratory margin-of-safety studies, reproductive safety studies, and blind multicenter field studies in client-owned animals. Therefore, when choosing a COX-2-selective or dual-inhibitor NSAID for clinical use, all in vivo data must be taken into account to understand comparative safety, and continued use must be based on the drug's performance in the individual being treated. Until head-to-head trials in multicenter blind studies are published, comments on comparative safety and effectiveness must be reserved.     

Trends in veterinary clinical and fundamental pharmacology: past and future in The Netherlands

Veterinary pharmacology has undergone a gradual development in the Netherlands during this century. Starting from a historical perspective the paper aims to provide an overview of future trends and important issues in the area of veterinary pharmacology and toxicology. It is pointed out that this discipline comprises several subdisciplines as the comparative aspect of both, pharmacology and toxicology, is inherent to veterinary medicine which has to address a broad variety of animal species. Thus, the comparison of drug effects, side effects, and drug disposition as well as the comparison of the species-specific susceptibility to xenobiotics are obvious challenges in this discipline. Several areas in clinical pharmacology are highlighted to indicate future research needs. Finally, the principles of Good Veterinary Practice are presented as the 'golden standard' in veterinary clinical pharmacology.     

Diethylstilboestrol—clinical pharmacology and alternatives in small animal practice

Diethylstilboestrol is currently only available in Australia for oral use in dogs and cats. As an orally and systemically active non-steroidal oestrogen, DES has been widely used in small animal veterinary medicine for a variety of indications. A review of the literature reveals that many of the recommendations for use are founded on anecdotal or unreported clinical observations. While many of the uses may be valid, accurate determinations of optimum dosing regimens have not been defined. This is especially unfortunate in view of the potential toxicity of DES to small animals. Nevertheless, particularly in cases of low-dose intermittent administration, oral DES appears indicated at least until data on alternative safe and effective interventions become available.     

Frontiers in anthelmintic pharmacology.

Research in anthelmintic pharmacology faces a grim future. The parent field of veterinary parasitology has seemingly been devalued by governments, universities and the animal industry in general. Primarily due to the success of the macrocyclic lactone anthelmintics in cattle, problems caused by helminth infections are widely perceived to be unimportant. The market for anthelmintics in other host species that are plagued by resistance, such as sheep and horses, is thought to be too small to sustain a discovery program in the animal health pharmaceutical industry. These attitudes are both alarming and foolish. The recent history of resistance to antibiotics provides more than adequate warning that complacency about the continued efficacy of any class of drugs for the chemotherapy of an infectious disease is folly. Parasitology remains a dominant feature of veterinary medicine and of the animal health industry. Investment into research on the basic and clinical pharmacology of anthelmintics is essential to ensure chemotherapeutic control of these organisms into the 21st century. In this article, we propose a set of questions that should receive priority for research funding in order to bring this field into the modern era. While the specific questions are open for revision, we believe that organized support of a prioritized list of research objectives could stimulate a renaissance in research in veterinary helminthology. To accept the status quo is to surrender.     

An introduction to principles of veterinary clinical pharmacology: General principles

Three hundred and sixty goats, pregnant from an estimated 72 days to almost full-term, aborted between 30 and 50 hours afterreceiving 0.25 or 0.5ml cloprostenol by subcutaneous or intramuscular injection. Despite close observation, no goat was seen aborting. All membranes and some foetal limbs were consumed, afterwhich the foetuses (and three live kids) were abandoned.

Fourteen goats died from blood poisoning due to CI. chauvoei between 30 and 40 hours after aborting. It is recommended that an immunisation programme precede the induction of abortion or premature parturition in the goat.     

Mastitis therapy and pharmacology.

Mastitis remains the most frequent cause of antibacterial use on dairy farms and contributes to a substantial portion of total drug and veterinary costs incurred by the dairy industry. Ultimately, the best outcome of mastitis therapy is a positive effect on the amount of marketed milk harvested and long-term survival of the cow. This article describes the strategies of therapy for bovine mastitis, with an emphasis on antibacterial and anti-inflammatory therapy.     

A review of the pharmacology and clinical uses of ivermectin

The avermectins were introduced in 1981 and constitute a potent new class of anthelmintic agents. They are naturally-derived products of microbial action displaying an exceptionally wide range of antiparasitic efficacy against internal and external parasites of domestic animals. This paper reviews their isolation and chemistry, mechanism of action, chemical efficacy and safety in cattle, sheep, swine, horses and dogs.     

A review of the pharmacology and clinical application of alfaxalone in cats

Alfaxalone-2-hydroxpropyl-β-cyclodextrin (alfaxalone-HPCD) was first marketed for veterinary use in Australia in 2001 and has since progressively became available throughout the world, including the USA, where in 2012 Food and Drug Administration (FDA) registration was granted. Despite the growing body of published works and increasing global availability of alfaxalone-HPCD, the accumulating evidence for its use in cats has not been thoroughly reviewed. The purpose of this review is: (1) to detail the pharmacokinetic properties of alfaxalone-HPCD in cats; (2) to assess the pharmacodynamic properties of alfaxalone-HPCD, including its cardiovascular, respiratory, central nervous system, neuromuscular, hepatic, renal, haematological, blood-biochemical, analgesic and endocrine effects; and (3) to consider the clinical application of alfaxalone-HPCD for sedation, induction and maintenance of anaesthesia in cats. Based on the published literature, alfaxalone-HPCD provides a good alternative to the existing intravenous anaesthetic options for healthy cats.